GRD Biotechnology Acquisition today registered to offer 4 million shares at $10 each. The new SPAC is not offering units with warrants.
The SPAC intends to focus on the Asian biotechnology sector.
No underwriter was listed in the S-1 registration statement.
Chairman and CEO Zhonghua Gao has more than 20 years of experience in biotechnology, human cell and gene biological testing, and general health, according to the S-1. He has served as Dean of the Gene Technology Research Institute, Chairman of Zhongjianlian Biotechnology Co., Ltd., and Chairman of Sichuan Gaorunde Biotechnology Co., Ltd.
GRD said it would apply for a NASDAQ listing under the symbol CGRD. Read more.
